Millipore Sigma Vibrant Logo

MAB1912 Anti-Procollagen Type I Antibody, NT, clone M-58

View Products on Sigmaaldrich.com
MAB1912
100 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited Availability
Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HIH(P)RCulture SupernatantMonoclonal Antibody
      Description
      Catalogue NumberMAB1912
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Procollagen Type I Antibody, NT, clone M-58
      References
      Product Information
      FormatCulture Supernatant
      Control
      • Skin tissue
      PresentationUnPurified tissue culture supernatant from a perfusion system, filtered through a 0.2μ micron membrane prior to vialing. Product contains 20%FBS and Ciprofloxacin at final concentration of 10μg/mL.
      Quality LevelMQ100
      Applications
      ApplicationDetect Procollagen Type I using this Anti-Procollagen Type I Antibody, N-terminus, clone M-58 validated for use in IH(P).
      Key Applications
      • Immunohistochemistry (Paraffin)
      Application NotesImmunohistochemistry: 1:10,000-1:50,000 (fresh frozen tissue sections.)

      Suitable for formaldehyde/formalin fixed paraffin sections, suggested starting dilution 1:100-1:1000, after treatment with 1% trypsin, 20 minutes at room temperature. Does not stain mature collagen fibers in tissue. Localized intracellularly in cells producing pro-collagen I. Not recommended for Western Blots Optimal working dilutions must be determined by end user.
      Biological Information
      ImmunogenHuman pro-collagen I.
      EpitopeN-terminus
      CloneM-58
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostRat
      SpecificityRecognizes Human pro-collagen I. MAB1912 labels the amino-terminal pro-peptide.
      IsotypeIgG
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos syndrome Classical type, Caffey Disease and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the growth factor. Two transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene. [provided by R. Dalgleish]
      Gene Symbol
      • COL1A1
      • OI4
      Non-Reactive Species
      • Hamster
      • Mouse
      • Rat
      Purification MethodUnpurified
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P02452 # Type I collagen is a member of group I collagen (fibrillar forming collagen).
      SIZE: 1464 amino acids; 138911 Da
      SUBUNIT: Trimers of one alpha 2(I) and two alpha 1(I) chains. Interacts with MRC2 (By similarity).
      SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular matrix (By similarity).
      TISSUE SPECIFICITY: Forms the fibrils of tendon, ligaments and bones. In bones the fibrils are mineralized with calcium hydroxyapatite.
      PTM: Proline residues at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains. & O-linked glycan consists of a Glc-Gal disaccharide bound to the oxygen atom of a post-translationally added hydroxyl group.
      DISEASE: SwissProt: P02452 # Defects in COL1A1 are the cause of Caffey disease [MIM:114000]; also known as infantile cortical hyperostosis. Caffey disease is characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones may also appear inflamed, with painful swelling and systemic fever often accompanying the illness. The bone changes usually begin before 5 months of age and resolve before 2 years of age. & Defects in COL1A1 are a cause of Ehlers-Danlos syndrome type I (EDS-I) [MIM:130000]; also known as Ehlers-Danlos syndrome gravis. Ehlers-Danlos syndrome is a genetically and phenotypically heterogeneous connective-tissue disorder characterized by loose- jointedness and fragile, velvety, stretchable, bruisable skin that heals with peculiar 'cigarette-paper' scars. EDS-I is an autosomal dominant trait. & Defects in COL1A1 are a cause of autosomal dominant Ehlers-Danlos syndrome type VII (EDS-VII) [MIM:130060]; which includes also Ehlers-Danlos syndrome type VII-A1. EDS-VII is characterized by arthrochalasis multiplex congenita, skin hyperextensibility and bruisability. & Defects in COL1A1 are a cause of osteogenesis imperfecta type I (OI-I) [MIM:166200]. OI-I is a dominantly inherited serious newborn disease characterized by bone fragility, normal stature, little or no deformity, blue sclerae and hearing loss in 50% of families. Dentinogenesis imperfecta is rare and may distinguish a subset of OI type I (formation of dentine). & Defects in COL1A1 are a cause of osteogenesis imperfecta type II (OI-II) [MIM:166210]; also known as osteogenesis imperfecta congenita. OI-II is lethal in the perinatal period and is charaterized by calvarial mineralization, beaded ribs, compressed femurs, marked long bone deformity and platyspondyly (congenital flattening of the vertebral bodies). & Defects in COL1A1 are a cause of osteogenesis imperfecta type III (OI-III) [MIM:259420]; also called progressively deforming osteogenesis imperfecta with normal sclerae. OI-III is characterized by progressively deforming bones, usually with moderate deformity at birth, sclerae is variable in color, dentinogenesis imperfecta and hearing loss are common. The stature is very short. & Defects in COL1A1 are a cause of osteogenesis imperfecta type IV (OI-IV) [MIM:166220]. OI-IV is charaterized by normal sclerae, moderate to mild deformity and variable short stature. Dentinogenesis imperfecta is common and hearing loss occurs in some patients. & Genetic variations in COL1A1 are associated with susceptibility to involutional osteoporosis [MIM:166710]; also known as senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mineral density, disrutption of bone microarchitecture, and the alteration of the amount and variety of non-collagenous proteins in bone. Osteoporotic bones are more at risk of fracture. & A chromosomal aberration involving COL1A1 is a cause of dermatofibrosarcoma protuberans (DFSP) [MIM:607907]. Translocation t(17;22)(q22;q13) with PDGF. DFSP is an uncommon, locally aggressive, but rarely metastasizing tumor of the deep dermis and subcutaneous tissue. It typically occurs during early or middle adult life and is most frequently located on the trunk and proximal extremities.
      SIMILARITY: SwissProt: P02452 ## Belongs to the fibrillar collagen family. & Contains 1 VWFC domain.
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      MAB1912 04053252465383

      Documentation

      Anti-Procollagen Type I Antibody, NT, clone M-58 MSDS

      Title

      Safety Data Sheet (SDS) 

      Anti-Procollagen Type I Antibody, NT, clone M-58 Certificates of Analysis

      TitleLot Number
      RAT ANTI-HUMAN PRO-COLLAGEN I 2465270
      RAT ANTI-HUMAN PRO-COLLAGEN I - 3249469 3249469
      RAT ANTI-HUMAN PRO-COLLAGEN I - 3257583 3257583
      RAT ANTI-HUMAN PRO-COLLAGEN I - 3269451 3269451
      RAT ANTI-HUMAN PRO-COLLAGEN I - 3272274 3272274
      RAT ANTI-HUMAN PRO-COLLAGEN I - 3728319 3728319
      RAT ANTI-HUMAN PRO-COLLAGEN I - 3815831 3815831
      RAT ANTI-HUMAN PRO-COLLAGEN I -2802652 2802652
      RAT ANTI-HUMAN PRO-COLLAGEN I AMINO-TERMINAL - 2506446 2506446
      RAT ANTI-HUMAN PRO-COLLAGEN I AMINO-TERMINAL - 2952691 2952691

      References

      Reference overviewApplicationPub Med ID
      Biological Effects Induced by Specific Advanced Glycation End Products in the Reconstructed Skin Model of Aging.
      Pageon, H; Zucchi, H; Dai, Z; Sell, DR; Strauch, CM; Monnier, VM; Asselineau, D
      BioResearch open access  4  54-64  2015

      Show Abstract
      26309782 26309782
      Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis.
      Lee, R; Perry, B; Heywood, J; Reese, C; Bonner, M; Hatfield, CM; Silver, RM; Visconti, RP; Hoffman, S; Tourkina, E
      Frontiers in pharmacology  5  140  2014

      Show Abstract
      24966836 24966836
      Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry.
      Reese, C; Lee, R; Bonner, M; Perry, B; Heywood, J; Silver, RM; Tourkina, E; Visconti, RP; Hoffman, S
      Frontiers in pharmacology  5  141  2014

      Show Abstract
      24999331 24999331
      Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy.
      Norsgaard, H; Kurdykowski, S; Descargues, P; Gonzalez, T; Marstrand, T; Dünstl, G; Røpke, M
      Archives of dermatological research  306  719-29  2014

      Show Abstract
      25027750 25027750
      Platelet-rich fibrin versus albumin in surgical wound repair: a randomized trial with paired design.
      Danielsen, Patricia L, et al.
      Ann. Surg., 251: 825-31 (2010)  2010

      Show Abstract
      20395860 20395860
      Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers.
      Zhi, K; Shen, X; Zhang, H; Bi, J
      Journal of experimental & clinical cancer research : CR  29  66  2010

      Show Abstract
      20529313 20529313
      Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model.
      Isaiah G Schauer, Steven J Ressler, David R Rowley, Isaiah G Schauer, Steven J Ressler, David R Rowley, Isaiah G Schauer, Steven J Ressler, David R Rowley, Isaiah G Schauer, Steven J Ressler, David R Rowley
      The Prostate  69  373-84  2009

      Show Abstract Full Text Article
      19021203 19021203
      Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue.
      Davis, DR; Zhang, Y; Smith, RR; Cheng, K; Terrovitis, J; Malliaras, K; Li, TS; White, A; Makkar, R; Marbán, E
      PloS one  4  e7195  2009

      Show Abstract Full Text Article
      Immunohistochemistry19779618 19779618
      SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion.
      Yunker, CK; Golembieski, W; Lemke, N; Schultz, CR; Cazacu, S; Brodie, C; Rempel, SA
      International journal of cancer. Journal international du cancer  122  2735-43  2008

      Show Abstract
      18350569 18350569
      MMP-21 is expressed by macrophages and fibroblasts in vivo and in culture.
      Tiina Skoog, Katja Ahokas, Christina Orsmark, Leila Jeskanen, Keiichi Isaka, Ulpu Saarialho-Kere
      Experimental dermatology  15  775-83  2006

      Show Abstract
      16984259 16984259

      Data Sheet

      Title
      RAT ANTI-HUMAN PRO-COLLAGEN I AMINO-TERMINAL

      Related Products & Applications

      Related Products

      Alternative Packsize

      Catalogue Number Description  
      MAB1912-K Rat Anti-Procollagen Type I, N-terminus, clone M-58 Show Pricing & Availability

      Product Families

      Categories

      Life Science Research > Antibodies and Assays > Primary Antibodies